Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
The chart shows the growth of an initial investment of $10,000 in Agilent Technologies Inc., comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Agilent Technologies Inc. (A) has returned -15.24% so far this year and 12.52% over the past 12 months. Looking at the last ten years, A has achieved an annualized return of 11.10%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
A
1M-2.88%
6M-18.39%
YTD-15.24%
1Y12.52%
5Y-2.56%
10Y11.10%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Agilent Technologies Inc. (A) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-1.75%
-8.48%
-4.10%
1.29%
2025
12.06%
-14.58%
-9.32%
-7.58%
4.35%
6.18%
-2.24%
10.76%
2.78%
14.04%
5.81%
-10.80%
2024
-5.85%
5.61%
6.19%
-6.25%
-4.62%
-0.28%
8.19%
0.48%
4.84%
-12.07%
-0.84%
-2.53%
2023
0.08%
-7.40%
-0.17%
-1.45%
-14.96%
2.80%
1.46%
-0.58%
-8.86%
-6.79%
24.68%
9.18%
2022
-12.38%
-7.24%
1.15%
-11.11%
7.75%
-7.11%
12.89%
-3.94%
-4.76%
12.73%
11.10%
-4.52%
2021
1.03%
1.14%
3.32%
4.41%
2.86%
6.21%
3.69%
13.90%
-10.00%
0.22%
-4.12%
5.64%
2020
-3.89%
-7.47%
-7.36%
10.35%
16.66%
0.37%
8.37%
3.59%
0.02%
0.31%
12.93%
0.77%
2019
14.36%
4.31%
0.47%
-3.04%
-14.58%
11.38%
-8.19%
2.13%
8.39%
-0.98%
5.57%
5.61%
2018
8.91%
-6.27%
-2.29%
-1.37%
-5.65%
-1.01%
7.63%
2.58%
4.75%
-8.33%
11.19%
-8.00%
2017
6.62%
4.84%
2.42%
4.06%
8.72%
-1.17%
0.34%
7.79%
-1.08%
5.82%
1.52%
-3.21%
2016
3.44%
11.38%
-3.04%
8.45%
-2.35%
0.13%
-6.94%
0.57%
3.36%
Performance Indicators
The charts below present risk-adjusted performance metrics for Agilent Technologies Inc. (A) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of A compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Agilent Technologies Inc. volatility is 1.48%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Liabilities And Equity (USD)
12.73B
10.76B
10.53B
10.71B
9.63B
9.45B
8.54B
8.43B
7.80B
7.48B
10.83B
10.69B
10.54B
9.06B
Equity Attributable To Parent (USD)
6.74B
5.85B
5.31B
5.39B
4.87B
4.75B
4.57B
4.83B
4.24B
4.17B
5.30B
5.29B
5.18B
4.31B
Equity Attributable To Noncontrolling Interest (USD)
Multiple major M&A transactions are underway across various sectors. Papa John's received a $1.5 billion privatization proposal from Irth Capital Management backed by Brookfield Asset Management. Shell sold Jiffy Lube to Monomoy Capital Partners for $1.3 billion. Meta acquired AI social network Moltbook, while Google completed its $32 billion acquisition of cloud security platform Wiz. Other notable deals include Agilent acquiring Biocare Medical for $950 million and Universal Health Services acquiring Talkspace for $835 million. Meanwhile, several retailers including Eddie Bauer and Saks Global are closing stores amid bankruptcy proceedings.
Benzinga•Caroline Ryan
AI Insight
Acquiring Biocare Medical for $950 million to expand its life sciences and diagnostics capabilities.
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
GlobeNewswire Inc.•Mordor Intelligence
AI Insight
Included among major companies in molecular diagnostics market. Positioned to benefit from technological innovations in diagnostic platforms and sequencing technologies.
Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million to strengthen its pathology and immunohistochemistry offerings. The deal is expected to close by Q4 fiscal 2026 and become accretive to EPS within 12 months. However, Agilent's stock has declined 5.60% over the past year and is currently trading below key moving averages, showing weak momentum despite the strategic acquisition.
Benzinga•Lekha Gupta
AI Insight
The acquisition of Biocare Medical is a strategic move expected to enhance revenue growth, margins, and EPS accretion. Biocare's strong double-digit growth since 2021 and 300+ specialized antibodies strengthen Agilent's market position in the high-growth IHC market. However, positive sentiment is tempered by the stock's recent underperformance and weak momentum indicators.
The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.
GlobeNewswire Inc.•Custom Market Insights
AI Insight
Listed among key market players in the expanding microplate systems sector, which is experiencing robust growth due to rising demand for high-throughput screening and advanced analytical capabilities.
The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Company reported full-year revenue of $6.83 billion in November 2023, demonstrating strong financial performance and benefiting from increased demand for advanced chromatographic instrumentation driven by pharmaceutical R&D and regulatory compliance needs.
The global automated sample preparation market is expected to expand at a 10.10% CAGR from 2025 to 2031, driven by pharmaceutical R&D investments, need for reproducibility, and AI/ML adoption. However, high initial costs and integration challenges with legacy systems remain significant barriers, particularly for smaller laboratories and SMEs.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Listed as a key player in the automated sample preparation market, positioned to benefit from the projected 10.1% CAGR market growth through 2031.
The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.
GlobeNewswire Inc.•Sns Insider
AI Insight
Listed as a key market player but no specific recent developments or product launches mentioned in the article.
The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology investments. Disease diagnostics account for 74.42% of revenue, with cancer diagnostics representing 60% of biopsy applications globally.
GlobeNewswire Inc.•Astute Analytica
AI Insight
Listed as a key market player in the growing anatomic pathology sector, benefiting from increased investments in precision oncology, molecular diagnostics, and advanced pathology infrastructure.
The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.
GlobeNewswire Inc.•Researchandmarkets.Com
AI Insight
Featured as a key player in the antibody optimization service market, positioned to gain from market expansion driven by complex disease treatment needs.
Agilent Technologies delivered strong Q4 FY2025 results with $1.86B revenue (9.4% reported growth, 7.2% core growth) and $1.59 non-GAAP EPS, marking the sixth consecutive quarter of sequential core growth acceleration. The company's diversified portfolio spanning chromatography, mass spectrometry, and lab automation, combined with its high-margin CrossLab services business, provides structural resilience during industry downturns. Trading at 23.7x EV/EBITDA with a modest P/E premium to historical averages, Agilent's valuation reflects strong execution, pricing power, and efficient capital allocation through buybacks and strategic acquisitions like BioVectra.
Investing.com•Gurufocus
AI Insight
Strong Q4 execution with 7.2% core growth, six consecutive quarters of sequential acceleration, industry-leading 54% gross margins, efficient cash conversion (~90% of net income), strategic acquisitions (BioVectra), and structural business model advantages through recurring CrossLab revenue. Valuation premium justified by superior execution and lower business risk relative to peers.
